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Multiple myeloma (MM) is hematological malignancy 
characterized by neoplastic proliferation of the mono-
clonal plasma cells [1]. MM affects mostly people after 
40 years of age and is estimated that annually con-
stitutes about 1% of all new cancer cases in western 
countries [2]. The main symptoms related to abnormal 
hematopoietic stem cells function include osteolytic 
lesions (caused by activation of osteoclasts as well 
as inhibition of osteoblasts), anemia and immunosu-
pression. Furthermore, uncontrolled production and 
secretion of monoclonal immunoglobulin by myeloma 
cell (plasmocyte) contributes to immunodeficiency 
[3]. Specific genetic aberrations and abnormal gene 
expression of few protooncogenes also accompany 
MM [4]. Although novel treatment modalities intro-
duced for MM significantly increased overall survival 
(OS), OS still reaches not more than 4 years [2]. MM 
still remains incurable disease and patients relapse 
in certain time-point. Therefore there is a necessity 
to generate novel therapeutical strategies. Results 
from allogenic stem cell transplantation (ASCT) did 
not prove survival benefit to MM patients mainly due 
to high treatment-related mortality. Interestingly, 
those patients who survived ASCT procedure ben-
efited from graft-versus–leukemia effect, what points 
that activation of immune system might effectively 
treat myeloma and anti-myeloma effect successfully 
protects MM patients from relapse. Other methods 
to induce specific anti-myeloma immunity were also 
introduced in the clinical practice. Here we review the 
current status of immunotherapeutical approaches 
for MM. 
Immune status of MM patients 
Immune system in MM is deficient due to a lot of fac-
tors associated with this disease. Low levels of normal 
B cells are not enough to assure sufficient immune 
control on MM. Kay et al. observed decrease of nor-
mal B lymphocytes, as well as their functional deficit 
characterized by impaired response for the myeloma 
antigens [5–7]. Reduced production of polyclonal im-
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Multiple myeloma (MM) is characterized by deep immunodeficiency 
caused by many factors including uncontrolled production of mono-
clonal immunoglobulin and inhibitory effect of microenvironment. 
despite the use of different therapeutic strategies as drug treatment, 
chemotherapy and stem cell transplantation still remains an incurable 
disease. Novel treatment modalities introduced for MM significantly in-
creased overall survival, but it still reaches not more than 4 years. There-
fore there is a necessity to generate novel therapeutical strategies that 
successfully improve quality of MM patients life and cause complete 
recovery. Tumor-associated antigens (TAA) are potential targets for can-
cer immunotherapy due to their limited expression on normal tissues or 
restriction to tumor cells. epitopes derived from TAA induce specific, 
cytotoxic T lymphocytes which are able to recognize and eradicate my-
eloma cells with good efficacy. These features allow to construct vari-
ous types of peptide-based vaccines, which could prolong MM patients 
life and lead to complete remission. in this work we have characterized 
(c/T), human telomerase reverse transcriptase (hTerT), X-box binding 
protein 1 (XBP-1), PAS domain-containing protein 1 (PASd-1), recep-
tor for hyaluronic acid–mediated motility (rHAMM), mucin 1 (MUc-1), 
wilms Tumor-1 (wT1), that might represent a target for peptide-based 
immunotherapy. results from first clinical trials on immunotherapy in 
MM were also characterized.
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munotherapy
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munoglobulin results in increased incidence of bac-
terial infections, which often contributes to death of 
MM patients [8]. It should be emphasized that level 
of CD19+ cells is lower in advanced stages than early 
stages. In contrast high levels of B lymphocytes were 
found in patients who responded for therapy [5]. 
The changes in T-cell subset are even more com-
plex. Mellstedt et al. described changes in T-cell sub-
sets including inversion of CD4:CD8 ratio, which is 
most pronounced in the progressive disease [9]. Lower 
Th1:Th2 of CD4+ ratios are due to decreased abso-
lute number of Th2 cells [10]. Moss et al. observed 
oligoclonal expansion of CD8+ cells which occurs in 
MM patients with paraproteinemia [11]. Prabhalla 
et al. found decrease and functional impairment of 
FOXP3+ T regulatory cells (Tregs) characterized by 
inability to suppress anti-CD3- mediated prolifera-
tion [12]. In contrary we found increased frequencies 
of Tregs in MM that modulated survival. Patients 
with higher percentage of Tregs lived significantly 
shorter when compared to those with lower percent-
ages of Tregs [13]. T cell receptor defects and down-
regulation of co-stimulatory molecules that par-
ticipate in signal transduction are also responsible 
for functional impairment of T cells [14]. MM den-
dritic cells (DCs) were characterized by low expres-
sion of HLA-DR as well as co-stimulatory molecules 
CD40 and CD80. They were also not able to present 
patient-specific tumor idiotype to autologous T cells 
[15, 16]. Additionally as a result of the disturbances 
in the amount of DCs and functional impairment, 
incapability to induction of T cells in MM patients 
occurs [15]. Finally, cells that are components of 
tumor microenvironment secrete certain cytokines 
that influence immune system. Immunosuppressive 
cytokines such as vascular endothelial growth fac-
tor (VEGF), transforming growth factor beta (TGF-β), 
tumor necrosis factor (TNF-α), interleukin 6 (IL-6), 
insuline-like growth factor 1 (IGF-1), fibroblast 
growth factor (FBF), angiopoietin 1 (Ang-1) inhibit 
immune response, promote growth and migration of 
myeloma cells and angiogenesis (Figure 1). Thereby 
immune control is limited and ineffective in MM 
patients and this information should be taken into 
consideration while designing immunotherapy trials 
for MM patients [16]. 
Tumor-associated antigens
The fundamental step for immunotherapy constitutes 
the identification of the proper target antigen that is 
exclusively expressed on myeloma cells. 
Initially, cancer/testis (C/T) antigens were discov-
ered in patients with melanoma as favorable targets 
for immunotherapy presenting limited expression on 
normal tissue. Members of C/T family antigens were 
found in a lot of tumors including hematological 
malignances and MM. C/T antigens are presented 
only on germ and placenta cells. [17]. Andrade et al. 
found that expression of more than six C/T antigens 
on myeloma cells correlated with shorter OS in MM 
patients [18]. C/T antigens could stimulate T-cell 
responses effectively, therefore they could represent 
good targets in cancer immunotherapy [19, 20]. 
Fig. 1. Immune modulation in tumor microenvironment
Antigen presenting cells (APc) display melanoma antigens that stimulate cytotoxic T lymphocytes (cTLs) to immunological 
response against myeloma cells. Immunosuppressive cytokines such as vascular endothelial growth factor (VEGF), transfor-
ming growth factor beta (TGF-β), tumor necrosis factor (TNF-α), interleukin 6 (IL-6), insuline-like growth factor 1 (IGF-1), 
fibroblast growth factor (FBF), angiopoietin 1 (Ang-1) which are present at microenvironment inhibit immune response and 
promote growth and migration of myeloma cells and angiogenesis. bone marrow stem cells (bMSc) adhesive and secretion 
function maintain tumor growth. Treg – regulatory T lymphocytes.
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The proof of possibility to induce antigen-spe-
cific CTLs that are able to recognize epitope pep-
tides derived from target antigen constitutes corner-
stone for peptide-based immunotherapy. In patients 
in advanced stage III MM Jungbluth et al. showed 
that expression of melanoma-associated antigen C1 
(MAGE-C1) increase with progression disease and 
melanoma antigen C1 (C/T-7, MAGE-C1) demon-
strated 87% expression on mRNA and 82% at protein 
level [17]. Jungbluth et al. also showed that expression 
of MAGE-C1 with progression disease and also higher 
levels of this antigen correlated with elevated rate of 
plasma cell proliferation. Anderson et al. primarily 
identified 13 novel MAGE-C1-derived peptides. They 
immunized HLA-A2 transgenic mice with cell-based 
vaccine and detected CTL responses for 3 immuno-
genic peptides CT-7959-968, CT-71083-1091 and CT-7998-1006. 
CT-7959-968 and CT-71083-1091 were recognized by specific 
CTLs, what represent an evidence that these mole-
cules presented on myeloma cells are immunogenic 
in MM [21].
Another C/T antigen-MAGE-A3/6 showed 100% 
expression on mRNA and 70% protein expression on 
immunohistochemistry samples of third stage MM 
[17]. Gene expression levels of MAGE-C1 and MAGE-
A3/6 demonstrated strong correlation with clinical 
status. Higher levels of MAGE-C1 were observed in 
stage III myeloma patients and MAGE -A3 was the 
most frequently detected C/T antigen of MAGE family 
in monoclonal gammopathy of undetermined signifi-
cance (MGUS). Jungbluth et al. confirmed positive cor-
relation between CT-7 expression and disease progres-
sion, as well as higher percentages of Ki-67-positive 
cells which indicate plasma cell proliferation. These 
results might suggest that CT-7 and MAGE-A3 play 
an important role in pathogenesis of MM and possibly 
participate in the deregulation of the cell cycle [17].
Moreno et al. found that MAGE-A3 gene expres-
sion is more frequent at relapse patients. High gene 
expression was associated with proliferative signa-
ture of the disease, which indicated poor clinical out-
come [22]. They also proved that high expression of 
MAGE-A3 is significantly related to shorter OS and 
event-free survival (EFS). 
Another C/T antigen LAGE-1 occurs in two 
alternative splicing variants a and b. Andrade et 
al. observed 49% expression in MM patients [18]. 
Their mRNA sequence is highly homologic with NY-
ESO-1. Lethe et al. found LAGE-1 specific CTLs. 
Notably, only the LAGE-1a protein is very similar to 
NY-ESO-1 protein [23]. In study of Carvalho et al., 
authors found that LAGE-1a is expressed frequently 
in MM patients. According to them, LAGE could elicit 
immune response against NY-ESO-1 and high homol-
ogy both of these C/T antigens might be useful for 
vaccine immunotherapy [20].
NY-ESO-1 is aberrantly expressed in certain per-
centage of primary myeloma cells, and its expres-
sion correlate with poor prognosis. Expression of NY-
ESO-1 is very low in MGUS and smoldering myeloma. 
MM patients with genetic abnormalities characterized 
by conventional cytogenetic analyses demonstrate 
increase frequency of NY-ESO-1. van Rhee et al. dis-
covered that this C/T antigen shows higher expression 
in relapsed patients than in newly diagnosed patients. 
They also found spontaneous NY-ESO-1157-165-specific 
T cells in peripheral blood of NY-ESO-1 positive MM 
patients using HLA-A*0201/ NY-ESO-1157-165 tetram-
ers. NY-ESO-1157-165-specific CTLs were able to kill 
primary MM cells. Moreover, they observed self-gen-
erated humoral response in MM patients also those 
with unfavorable cytogenetic abnormalities [24]. All 
of this features demonstrated that NY-ESO-1 might 
be an excellent target for immunotherapy.
SPAN-Xb is spermatid-specific protein which 
restricted expression was found in testis and on 
MM cells. Wang et al. were able to detect antibody 
response against this C/T antigen [25]. Frank et 
al. identified two immunogenic peptides and cre-
ated the third heterolytic peptide which was even be 
more immunogenic [26]. They also observed CD8+ 
lymphocytes specific for all three SPAN-Xb-derived 
peptides and their cytotoxic function using ELISPOT 
assay [26, 27]. 
Sp-17 is spermatozoa protein involved in the reac-
tion of acrosome during fertilization, which expres-
sion in healthy donors is limited to testis. This C/T 
antigen occurs on both mRNA and protein levels in 
30% of patients with MM. Wang et al. found that SP-17 
gene expression depended on promoter methylation 
[28]. Chriva-Internati et al. generated specific CTLs 
from MM patients using recombinant Sp-17 protein 
[29]. They found that these specific CTLs were able 
to lyse MM cells through perforin-mediated pathway. 
Due to ability to induce specific CTLs and limited 
expression in healthy tissue Sp-17 might be an excel-
lent target for immunotherapy of MM patients. 
Human telomerase reverse transcriptase (hTERT) 
represents widely expressed TAA, which activity is 
found in >85% tumors and protects telomeric ends of 
chromosomes from degradation [30]. Due to limited 
presence in other human tissues hTERT might con-
stitute an excellent target for cancer immunotherapy 
[31]. Kryukov et al. found that hTERT specific CTLs, 
which were stimulated by hTERT-pulsed dendritic 
cells demonstrated complete cytotoxic activity against 
ARH77 hTERT-positive myeloma cell line [32]. ARH77 
hTERT- specific immune response was manifested by 
secretion of INF-γ and effective lysis of MM cells.
X-box binding protein 1 (XBP-1) could represent 
another target for MM [33]. This antigen is a tran-
scription factor that binds promoter of human major 
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histocompatibility complex class II [34]. Expression 
occurs constitutively in all MM cells and MM cell 
lines. Function of XBP-1 is required for the terminal 
differentiation of B lymphocytes to plasma cells and 
enables immunoglobulin secretion [35]. Wen et al. 
found that IL-6 induces expression of XBP-1 gene 
in MM cells and XBP-1 participates in proliferation 
of myeloma cells [36]. Bagratuni et al. found that 
low expression of XBP-1 gene correlated with better 
outcome [37]. Furthermore, low level of this tran-
scription factor allowed to predict beneficial effect 
of thalidomide treatment. Bae et al. observed and 
characterized two stable heterolytic XBP-1-derived 
HLA-A2 restricted peptides [38]. XBP-1 antigen-spe-
cific CTLs could secrete IFN-γ and revealed specific 
proliferation in response to myeloma cells in HLA-
A2-restrickted and antigen-specific way. They also 
showed ability of XBP-1-specific CTLs to lyse mye-
loma cells in all tested MM cell lines (McCAR, MM1S 
and U266). These results confirmed that XBP-1 
might represent specific target for vaccine-based 
immunotherapy in MM. 
PAS domain-containing protein 1 (PASD-1) was 
investigated in diffuse large B-cell lymphoma cells 
[38]. Sahota et al. confirmed expression on mRNA 
and protein level on MM cells both in cell lines 
RPMI8226 and THIEL as well as patients samples 
[39]. PASD-1 protein level was present in almost of 
95% all cells, but transcripts were demonstrated in 
only 27-40% of cells.
Receptor for hyaluronic acid–mediated motility 
(RHAMM) physiologically occurs in humans only in 
the thymus, placenta and testis. Initially Mohapatra 
et al. reported that this molecule participates in cell 
migration and transition cells through G2 phase to 
M phase in cell cycle [40, 41]. RHAMM plays signifi-
cant role in formation of mitotic spindle and angio-
genesis [42]. In MM the higher RHAMM expression 
is associated with poor prognosis [43]. Greiner et al. 
identified two immunogenic RHAMM epitopes R3 and 
R5 in acute myeloid leukemia (AML). They also gen-
erated RHAMM-R3-specific CTLs which were able to 
kill AML blast [44].
Mucin 1 (MUC-1) is transmembrane type I glyco-
protein occurs in MM cell as well as in other hemato-
logical malignances [45]. Overexpression of this TAA 
contributes to increased tumor growth and survival 
through activate NF-κB and β-catenin pathway [46]. 
Choi et al. observed presence and functional activity 
of MUC-1- specific CTLs in MM patients [47].
Wilms Tumor-1 (WT1) is universal TAA that 
occurs in adults in a few normal tissue for example 
stromal cells, Sertolie cells, granulose cells and kid-
ney’s podocytes. This restricted expression pattern 
causes WT-1 to represent excellent target to cancer 
immunotherapy [48]. Azuma et al. generated CTLs 
WT-1-specific which were competent to lyse efficiently 
MM cells in HLA class I-restricted manner [49]. All of 
described TAA are detailed characterized in Table I.
clinical trials of peptide-based vaccines 
Kuball et al. described results of the clinical trial on 
peptide immunotherapy in 5 MM patients with ad-
vanced disease. Patients received two different types 
of vaccines. They were injected six times by vaccines 
Table I. Tumor-associated antigens expressed in multiple myeloma
Antigen Expression Epitopes cTL references
MAge-c1 (cT-7) c/T – + [19]
MAge-A3 c/T MAge-A3/ HlA-A *6801 + [19]
lAge-1 c/T – + [23]
NY-eSo-1 c/T NY-eSo-1157-165 + [24]
SPAN-Xb c/T – + [26]
Sp17 c/T – + [29]
hTerT male germ cells, activated, lymphocytes, – + [32]
XBP-1 skeletal muscles, secretory cells in pancreas and salivary glands + + [37]
PASd-1 testis – – [39]
RHAMM thymus, placenta, testis R3 + [52]
MUc-1 cancers MUc-179-87; MUc-1138-178 – [45]
wT-1 stromal cells, sertolie cells, podocytes, – + [49]
c/T – cancer testis, cTl – specific cytotoxic T lymphocytes which are able to recognize tumor cells
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containing CpG7909, Montanide ISA51 and either 
MUC-179-87 and PADRE or the oligomer MUC-1138-178 
including epitopes for both CD4+ and CD8+ lym-
phocytes. Authors did not find any vaccine-reactive 
T lymphocytes after vaccination, however before both 
functional and non-functional reactive T cells were 
observed. It might suggest that vaccine could  induce 
anergy or exhaustion of T cells. Subsequently in this 
study authors could not observe any clinical benefits 
[50].
Rapoport et al. studied whether adoptive cell 
transfer of vaccine-primed autologous T lymphocytes 
might induce immune response against TAA repre-
sented by hTERT and surviving. Patients are ran-
domized based on HLA-A2 expression. 28 HLA-A2 
positive patients received pneumococcal conjugate 
vaccine (PCV) and multipeptide tumor antigen vac-
cine containing peptides derived from hTERT and 
survivin. 26 HLA-A2 negative patients of control arm 
were only vaccinated against PCV. Patients received 
ASCT and subsequently they were vaccinated three 
times after infusion of T cells. Immune response to 
the tumor-derived antigen was detectable in 36% 
patients in HLA-A2 positive patients. Although the 
immunization of hTERT and survivin before and 
after ASCT improved cellular and humoral antitumor 
immunity, the clinical benefit of vaccination could 
not be noted [51].
Tsuboi et al. performed vaccination of 57 years old 
chemotherapy-resistant MM patient. Vaccine included 
Montanide ISA51 as an adjuvant and HLA-A*2402-
restricted 9-mer WT1 peptide. Patient was injected 
intradermally during 12 weeks once a week. After 
vaccination 60% decrease of cancer cells in the bone 
marrow (BM) as well as lowering M protein level in 
urine from 3.6 to 0.6 g/day was observed. They also 
showed increased amount of WT-1-tetramer-specific 
T cells, as well as increase from 27% to 38.6% the fre-
quency CD107a/b+ cells fraction responding to WT-1 
peptide. Interestingly, the amount CXCR4 positive 
cells increased in BM and decreased in peripheral 
blood indicating that WT-1-specific CTLs might effec-
tively migrate to tumor site after vaccination [48].
Schmitt et al. vaccinated AML, myelodysplastic 
syndrome (MDS) and four MM patients with RHAMM-
derived peptide R3 with emulsificated incomplete 
Freund adjuvant followed by GM-CSF [52]. Patients 
received vaccine 4 times at biweekly intervals. They 
observed decrease of free light chains in serum 
in 50% MM patients. These results confirmed that 
RHAMM and their highly immunogenic peptide R3 
might be novel target in cancer immunotherapy, due 
to their ability to induce clinical and immunological 
response. Two years later the same group conducted 
study on patients with hematological malignances 
including MM with higher dose of R3 peptide. They 
observed that higher dose did not improve response 
to therapy [53]. The clinical trials results are sum-
marized in Table II. 
This review summarizes identified targets for 
immunotherapy and results from first clinical trials in 
MM. MM is characterized by deep immunodeficiency 
caused by many factors including microenvironment. 
Limited efficacy of first peptide-based immunothera-
peutical approaches point that more complex therapeu-
tical modalities including incorporating simultaneous 
administration of drugs able to shape microenviron-
ment, should be added to the treatment. 
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